GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AMAG Pharmaceuticals Inc (NAS:AMAG) » Definitions » Net Margin %

AMAG Pharmaceuticals (AMAG Pharmaceuticals) Net Margin % : 10.42% (As of Sep. 2020)


View and export this data going back to 1986. Start your Free Trial

What is AMAG Pharmaceuticals Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. AMAG Pharmaceuticals's Net Income for the three months ended in Sep. 2020 was $9.7 Mil. AMAG Pharmaceuticals's Revenue for the three months ended in Sep. 2020 was $93.1 Mil. Therefore, AMAG Pharmaceuticals's net margin for the quarter that ended in Sep. 2020 was 10.42%.

The historical rank and industry rank for AMAG Pharmaceuticals's Net Margin % or its related term are showing as below:


AMAG's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -162.58
* Ranked among companies with meaningful Net Margin % only.

AMAG Pharmaceuticals Net Margin % Historical Data

The historical data trend for AMAG Pharmaceuticals's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AMAG Pharmaceuticals Net Margin % Chart

AMAG Pharmaceuticals Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.84 -0.57 -40.64 -14.51 -143.21

AMAG Pharmaceuticals Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -28.57 -223.67 -35.67 -25.10 10.42

Competitive Comparison of AMAG Pharmaceuticals's Net Margin %

For the Biotechnology subindustry, AMAG Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AMAG Pharmaceuticals's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AMAG Pharmaceuticals's Net Margin % distribution charts can be found below:

* The bar in red indicates where AMAG Pharmaceuticals's Net Margin % falls into.



AMAG Pharmaceuticals Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

AMAG Pharmaceuticals's Net Margin for the fiscal year that ended in Dec. 2019 is calculated as

Net Margin=Net Income (A: Dec. 2019 )/Revenue (A: Dec. 2019 )
=-467.661/326.546
=-143.21 %

AMAG Pharmaceuticals's Net Margin for the quarter that ended in Sep. 2020 is calculated as

Net Margin=Net Income (Q: Sep. 2020 )/Revenue (Q: Sep. 2020 )
=9.702/93.106
=10.42 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AMAG Pharmaceuticals  (NAS:AMAG) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


AMAG Pharmaceuticals Net Margin % Related Terms

Thank you for viewing the detailed overview of AMAG Pharmaceuticals's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


AMAG Pharmaceuticals (AMAG Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1100 Winter Street, Waltham, MA, USA, 02451
AMAG Pharmaceuticals Inc primarily uses its nanoparticle technology to develop therapeutic compounds to treat anemia in patients suffering from chronic kidney disease, as well as imaging agents that assist in identifying cancerous tumors. The company recently received Food and Drug Administration approval for Feraheme, a novel iron replacement drug for CKD patients suffering from anemia, and also offers GastroMARK, an imaging aid used with magnetic resonance imaging. Most of the revenues are generated through the sale of Feraheme and Makena which is a hydroxyprogesterone caproate injection.
Executives
Camber Capital Management Lp 10 percent owner 101 HUNTINGTON AVENUE, SUITE 2101, BOSTON MA 02199
Anthony Casciano officer: Chief Operating Officer C/O AMAG PHARMACEUTICALS, INC. 1100 WINTER STREET WALTHAM MA 02451
Brian Piekos officer: Interim CFO C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
David Edward Johnson director, 10 percent owner 590 MADISON AVENUE, NEW YORK NY 10022
James R Sulat director
Davey Scoon director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
John A. Fallon director C/O INSULET CORPORATION, 9 OAK PARK DRIVE, BEDFORD MA 01730
Anne M. Phillips director C/O TREVENA, INC., 1018 WEST 8TH AVENUE, KING OF PRUSSIA PA 19406
Paul R. Fonteyne director C/O RESTORBIO, INC., 501 BOYLSTON STREET SUITE 6102, BOSTON MA 02116
Gino Santini director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Scott Dunseth Myers director, officer: President & CEO C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Kelly Schick officer: Chief Human Resources Officer C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd. 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022

AMAG Pharmaceuticals (AMAG Pharmaceuticals) Headlines

From GuruFocus